What if

an employee benefit could be life-changing

Beating cancer starts with knowing you have it

The earlier cancer is found, the higher the chance everyone wins: likely better outcomes for those finding it and greater peace of mind for those without it. Offering Galleri®, a multi-cancer early detection test, was found to encourage employees to join, stay, and understand they’re part of a workplace that truly cares.1

Employees say the Galleri test is the #1 ranked health benefit

Most cancers are not tested for today

Cancer is the most feared disease.2 Today, routine cancer screenings fail to detect the majority of invasive cancers.3 As a result, these cancers go undetected until they have progressed to an advanced stage where outcomes are often poor and treatment costs are high.4 – 7

72% of invasive cancers do not have screening tests 72% of invasive cancers do not have screening tests

Introducing the Galleri test

The Galleri test is a groundbreaking and potentially life-changing advancement in cancer detection for adults with an elevated risk for cancer, such as those aged 50 or older.

With the Galleri test, employees could receive the benefits of early detection of multiple cancers through a simple blood draw.

50+ cancer types detected

including cancers employees aren’t routinely screened for today9,10

0.5% false-positive rate

to help minimize unnecessary medical procedures9

89% accuracy

in predicting the location of the cancer, directing diagnostic workup9

The Galleri test is supported by large clinical studies.

The Galleri test is designed to integrate seamlessly to fit your needs 

We offer a flexible partnership model that is customized to your needs. 
Our efforts towards seamless integration will provide surround-sound marketing campaigns to drive enrollment, and wraparound services, including telemedicine consultations and support services, to ensure a positive experience.


Eligibility verification + test ordering through convenient online portal


Blood draw at a local lab facility


Return of results within 10 business days + support services

Speak with our team about offering the Galleri® test as an employee benefit

To discuss how the Galleri test could fit within your organization, please fill out the form below and a GRAIL representative will reach out to you shortly.

If you’re a patient, represent a health system, or are a healthcare provider, please reach out to us via contact forms on those pages.

* required

Recaptcha Failed

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you.

We look forward to speaking with you soon.

Important Safety Information

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected” does not rule out cancer. A test result of Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

Laboratory / Test Information

GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

Sign up for email

Sign up below to receive the latest news on the Galleri test, relevant information and helpful resources for employee benefits decision makers.

* required

This site is protected by reCAPTCHA, and the Google Privacy Policy and Terms of Service apply.

Thank you for signing up to learn more about the Galleri® test.

Let us know if you’d also like to speak with our team directly about offering the Galleri® test as an employee benefit.

  1. Market research data on file 2020. Study demographics included 314 respondents, age 40+, who were employed full-time at larger organizations.
  2. Vrinten C, McGregor LM, Heinrich M, von Wagner C, Waller J, Wardle J, Black GB. What do people fear about cancer? A systematic review and meta-synthesis of cancer fears in the general population. Psycho-Oncology. 2017 Aug;26(8):1070 – 1079.
  3. Screening includes methods with USPSTF A or B rating. SEER*Stat Database: Incidence — SEER 18 Regs Research Data, Nov 2017 Sub. Includes persons aged 50+ diagnosed 2006 – 2015.
  4. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence — SEER 18 Regs Research Data, Nov 2018 Sub. Includes persons aged 50 – 79 diagnosed 2006 – 2015. Early/​Localized” includes invasive localized tumors that have not spread beyond organ of origin. Late/​Distant Metastases” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body.
  5. Based on stage II and stage IV breast, colorectal, and lung cancer, and metastatic/non-metastatic pancreatic cancer.
  6. Banegas MP, Yabroff KR, O’Keeffe-Rosetti MC, et al. Medical Care Costs Associated With Cancer in Integrated Delivery Systems. J Natl Compr Canc Netw. 2018;16(4):402 – 10.
  7. DaCosta Byfield S, Nash Smyth E, Mytelka D, et al. Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population. J Med Econ. 2013;16(12):1379 – 86.
  8. American Cancer Society. Lifetime Risk of Developing or Dying From Cancer. [updated 2020 Jan 13; cited 2021 Feb 18]. Available from: https://www.cancer.org/healthy…
  9. Klein E, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test. Oral presentation at: American Association for Cancer Research; April, 2021; LB013.
  10. The Galleri test does not detect all cancers nor does it measure your genetic risk of developing cancer in the future. It should be used in addition to routine screening tests your healthcare provider recommends.